Please ensure Javascript is enabled for purposes of website accessibility

Why VBI Vaccines Stock Is Skyrocketing Today

By Keith Speights – Aug 27, 2020 at 11:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are fired up about an analyst's enthusiastic upgrade of the biotech stock.

What happened

Shares of VBI Vaccines (VBIV -0.95%) were up 45% as of 11:18 a.m. EDT on Thursday after rising as much as 62% earlier in the session. The huge jump came after Raymond James analyst Steven Seedhouse upgraded the stock from outperform to strong buy and raised his price target from $8 to $9.

So what

Analyst upgrades usually help stocks -- and especially small biotech stocks. But the massive gain for VBI Vaccines is certainly out of the ordinary.

Rocket flying over a red line with an arrow trending upward

Image source: Getty Images

The main reason why investors are so excited stemmed more from the comments by the analyst than the upgrade itself. Seedhouse stated in a note to investors that VBI's COVID-19 vaccine candidate "could be the best vaccine of them all (including all of the first movers and Operation Warp Speed members)." The research note added, "VBI may be in an entirely different ballpark for potency vs. any other vaccine we've seen."

If this take is right, VBI could eventually become the leader among all of the drugmakers with novel coronavirus vaccines in development. It's important to note, though, that Seedhouse's optimism is based solely on preclinical data. Clinical testing in humans doesn't always produce results similar to those seen in preclinical testing.

Now what

Investors shouldn't have to wait for too long to know how VBI's COVID-19 vaccine fares in clinical testing. The company has selected two vaccine candidates to advance into a phase 1/2 clinical study. Assuming VBI receives a green light from the FDA, the study will likely begin in late 2020.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

VBI Vaccines Inc. Stock Quote
VBI Vaccines Inc.
VBIV
$0.73 (-0.95%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.